Lv1
29 积分 2023-07-24 加入
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
7个月前
已完结
GCKR and GCK polymorphisms are associated with increased risk of end-stage kidney disease in Chinese patients with type 2 diabetes: The Hong Kong Diabetes Register (1995–2019)
7个月前
已完结
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
7个月前
已完结
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction
8个月前
已完结
CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients
8个月前
已完结
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
8个月前
已完结
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
8个月前
已完结
Challenges and opportunities in real‐world evidence on the renal effects of SGLT ‐2 inhibitors
8个月前
已完结
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
9个月前
已完结
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
9个月前
已完结
皖公网安备34019202002308
